GLSI earnings analysis
What we found in GLSI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided excerpt does not include the income statement, balance sheet, cash flow statement, segment data, or MD&A, so revenue, margins, EPS, liquidity, and cash-flow trends cannot be assessed. The principal disclosed concern is ineffective disclosure controls as of June 30, 2026, driven by multiple accounting, IT, and personnel-process weaknesses. Management is developing a remediation plan, while the filing reports no material changes to the risk factors from the December 31, 2025 Form 10-K.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No Material Legal Proceedings
- The company reported that it is not currently a party to any material legal proceedings and is unaware of any pending or threatened proceeding expected to have a material adverse effect.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material Internal-Control Weaknesses
- Disclosure controls and procedures were concluded to be ineffective as of June 30, 2026, due to material weaknesses involving segregation of duties, written accounting and IT policies, financial-reporting systems, stock-award software, and employee-expense approvals.
- Control Remediation Remains Pending
- Management stated that no change during the most recent fiscal quarter materially affected, or was reasonably likely to materially affect, internal control over financial reporting; however, a remediation plan is still being developed as of June 30, 2026.
- No Updated Risk-Factor Disclosure
- The filing states there have been no material changes from the risk factors disclosed in the Form 10-K for the year ended December 31, 2025; therefore, no new risk-factor update was identified.
What they said about what is next.
The provided filing excerpt contains no quantitative revenue or EPS outlook; management’s outlook is not included.
The filing reads worse than the one before it.
What came before.
- 10-Q · June 3, 2026
- Greenwich LifeSciences reported a net loss of $5.66 million for Q1 2026, an increase from $2.74 million in the same period last year. The company continues to focus on its Phase III clinical trial, Flamingo-01, while…
- 10-K · June 1, 2026
- Greenwich LifeSciences reported substantial financial losses and no revenues for the year ended December 31, 2025. The company incurred a net loss of $19.4 million, which continues a trend of increasing net losses,…
- 10-Q · August 14, 2025
- Greenwich LifeSciences reported Q2 2025 net loss of $4,025,278 (EPS $(0.30)), wider than Q2 2024 net loss of $2,606,682 (EPS $(0.20)). Cash declined to $3,125,101 from $4,091,990 at year-end, while operating cash used…
- 10-Q · May 20, 2025
- Greenwich LifeSciences reported a Q1 2025 net loss of $3,258,362 (EPS $(0.25)), worsening from a net loss of $2,473,195 (EPS $(0.19)) in Q1 2024. Cash declined to $2,749,959 as of March 31, 2025 from $4,091,990 at…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GLSI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever